Ocean Biomedical faces potential Nasdaq delisting for failing to file key financial reports.

Ocean Biomedical, Inc., a Providence-based biopharma company, received a notice from Nasdaq for failing to file its Quarterly Report and yearly report. This non-compliance could lead to delisting from the Nasdaq Capital Market, with a decision expected on December 16. The company is focused on developing treatments for lung cancer, brain cancer, pulmonary fibrosis, and malaria.

November 22, 2024
3 Articles